Advertisement

How to improve issuing, transfusion and follow-up of blood components in Southern and Eastern Mediterranean countries? A benchmark assessment

Published:November 24, 2022DOI:https://doi.org/10.1016/j.transci.2022.103616

      Abstract

      To determine the existence of guidelines regarding the appropriate clinical use of blood and blood components, transfusion requests, and blood issuing/reception documents and procedures. The different bedside transfusion organizations/processes and hemovigilance are also analyzed. The ultimate objective is to identify safe potential options in order to improve blood safety at the lowest cost. Data emanating from eight Arabic eastern/southern Mediterranean countries who responded to five surveys were collected and tabulated. National recommendations for the clinical use of blood components especially for hemoglobinopathies are lacking in some countries. In matter of good practices in the prescription, issuing and reception of BCs, efforts were made either on national or local basis. Procedures regarding patient information and ethical issues are still lacking. Almost all Mediterranean countries apply two blood testing procedures on each patient sample. Only Morocco, Tunisia and Algeria perform bed side blood group testing; Egypt and Lebanon perform antibody screen and antiglobulin cross matching universally. Automation for blood testing is insufficiently implemented in almost all countries and electronic release is almost absent. National hemovigilance policy is implemented in Tunisia, Morocco, and Lebanon but the reporting system remains inoperative. Insufficient resources severely hinders the implementation of expensive procedures and programs; however, the present work identifies safe procedures that might save resources to improve other parts in the transfusion process (e.g. electronic release to improve safety in issuing). Moreover, setting up regulations regarding ethics in transfusing recipients along with local transfusion committees are crucially needed to implement hemovigilance in transfusion practice.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aprili G.
        Safety in transfusion medicine.
        Blood Transfus. 2008; 6: 121-126
        • M0BC Koh
        • Alcantara R.
        Transfusion errors and management.
        ISBT Science Series. 2009; 4: 216-220
        • Haddad A.
        • Elgemmezi T.
        • Chaїb M.
        • et al.
        Quality and Safety measures in transfusion practice: The experience of eight Southern/Eastern Mediterranean countries.
        Vox Sang. 2020; 115: 405-423
      1. World Health Organization. Global Safety Report on Blood Safety and Availability, 〈https://apps.who.int/iris/bitstream/handle/10665/254987/9789241565431-eng.pdf〉; 2016 [accessed 30 January 2022].

        • World Health Organization
        Regional Office for the Eastern Mediterranean.
        Strategic Framework for Blood Safety and Availability. 2016; ([accessed 25 January 20019]): 2016-2025
      2. Centers for Disease Control and Prevention. Blood Safety Basics. 〈https://www.cdc.gov/bloodsafety/basics.html〉; 2018 [accessed 30 January 2022].

        • Haddad A.
        • Benajiba M.
        • Hmida S.
        • et al.
        How to manage transfusion systems in developing countries: The Experience of Eastern and Southern Mediterranean countries.
        Transfus Med. 2020; 30: 7-15
        • Bou Assi T.
        • Haddad A.
        • Haddad L.
        • Garraud O.
        Can a decentralized blood supply system reach 100% voluntary nonremunerated donation?.
        Int J Health Plann Management. 2018; 33: e883-e891
        • Haddad A.
        • Bou Assi T.
        • Garraud O.
        How Can Eastern/Southern Mediterranean Countries Resolve Quality and Safety Issues in Transfusion Medicine?.
        Front Med. 2018; 5: 45
      3. The World Bank, http://www.worldbank.org; 2019 [accessed 29 January 2019].

      4. PopulationData.net. Atlas des populations et pays du monde, 〈https://www.populationdata.net/〉; 2019 [accessed 29 January 2019].

        • Saffi M.
        • Howard N.
        Exploring the Effectiveness of Mandatory Premarital Screening and Genetic Counseling Programmes for β-Thalassaemia in the Middle East: A Scoping Review.
        Public Health Genomics. 2015; 18: 193-203
        • De Sanctis V.
        • Kattamis C.
        • Canatan D.
        • et al.
        β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint.
        Mediterr J Hematol Infect Dis. 2017; 9e2017018
        • El-Hazmi M.A.
        • Al-Hazmi A.M.
        • Warsy A.S.
        Sickle cell disease in Middle East Arab countries.
        Indian J Med Res. 2011; 134: 597-610
        • Modell B.
        • Darlison M.
        Global epidemiology of haemoglobin disorders and derived service indicators.
        Bull World Health Organ. 2008; 86: 480-487
      5. World Health Organization. The clinical use of blood,〈〉〈https://www.who.int/bloodsafety/clinical_use/en/Handbook_EN.pdf〉; 2002 [accessed 30 January 2022].

      6. European Directorate for the Quality of Medicine and Healthcare. Guide to the preparation, use and quality assurance of blood components, 〈https://freepub.edqm.eu/publications/AUTOPUB_48/detail〉; 2020 [accessed 16 June 2021].

      7. World Health Organization. Clinical transfusion process and patient safety, the WHO, Aide-mémoire, 〈https://www.who.int/bloodsafety/clinical_use/who_eht_10_05_en.pdf〉; 2005 [accessed 30 January 2022].

        • National Clinical Guideline Centre
        Blood Transfusion. London: National Institute for Health and Care Excellence (UK); 2015 Nov. (NICE Guideline.
        Patient information. 2015; 20 (accessed 16 June 2021)
        • Linden J.V.
        • Paul B.
        • Dressel K.P.
        A report of 104 transfusion errors in New York State.
        Transfusion. 1992; 32: 601-606
        • Andreu G.
        • Morel P.
        • Forestier F.
        • et al.
        Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998.
        Transfusion. 2002; 42: 1356-1364
        • Bolton-Maggs P.H.B.
        Conference report: International Haemovigilance Seminar and the SHOT Annual Symposium.
        Transfus Med. 2019; 29 (10-12 July 2018): 247-252
        • Stainsby D.
        • Russell J.
        • Cohen H.
        • et al.
        Reducing adverse events in blood Transfusion.
        Br J Haematol. 2005; 131: 8-12
        • Figueroa P.I.
        • Ziman A.
        • Wheeler C.
        • et al.
        Nearly Two Decades Using the Check-Type to Prevent ABO-Incompatible Transfusions.
        Am J Clin Pathol. 2006; 126: 422-426
        • Glisch C.
        • Jawa Z.
        • Brener A.
        • et al.
        Evaluation of a two-sample process for prevention of ABO mistransfusions in a high volume academic hospital.
        BMJ Open Quality. 2018; 7e000270
        • Dzik W.H.
        • Murphy M.F.
        • Andreu
        • et al.
        An international study of the performance of blood sample collection.
        Vox Sang. 2003; 85: 40-47
        • Murphy M.F.
        • Stearn B.E.
        • Dzik W.H.
        Current performance of patient sample collection in the UK.
        Transfus Med. 2004; 14: 113-121
        • Chiaroni J.
        • Legrand D.
        • Dettori I.
        • et al.
        Analysis of ABO discrepancies occurring in 35 French hospitals.
        Transfusion. 2004; 44: 860-864
        • Thomas W.
        • Davies J.
        • Asamoah A.
        • et al.
        Two samples for blood transfusion: single centre experience.
        Transfus Med. 2014; 24: 209-212
        • Sazama K.
        Reports of 355 transfusion-associated deaths: 1976-1985.
        Transfusion. 1990; 30: 583-590
        • Ansari S.
        • Szallasi A.
        “Wrong blood in tube”: solutions for a persistent problem.
        Vox Sang. 2010; 100: 298-302
        • Levy G.
        [The pretransfusion bedside agglutination test is not a "Gold Standard"].
        Transfus Clin Biol. 2008; 15: 318-321
        • Frietsch T.
        • Thomas D.
        • Schöler M.
        • et al.
        Administration Safety of Blood Products - Lessons Learned from a National Registry for Transfusion and Hemotherapy Practice.
        Transfus med hemother. 2017; 44: 240-254
        • Dujardin P.P.
        • Salmi L.R.
        • Ingrand P.
        Errors in interpreting the pretransfusion bedside compatibility test: an experimental study.
        Vox Sang. 2000; 78: 37-43
        • Ingrand P.
        • Surer-Pierres N.
        • Houssay D.
        • et al.
        Reliability of the pretransfusion bedside compatibility test: association with transfusion practice and training.
        Transfusion. 1998; 38: 1030-1036
        • Khetan D.
        • Katharia R.
        • Pandey H.C.
        • et al.
        Assessment of bedside transfusion practices at a tertiary care center: A step closer to controlling the chaos.
        Asian J Transfus Sci. 2018; 12: 27-33
        • Lange J.
        • Selleng K.
        • Heddle N.M.
        • et al.
        Coombs' crossmatch after negative antibody screening--a retrospective observational study comparing the tube test and the microcolumn technology.
        Vox Sang. 2010; 98: e269-e275
        • Heddle N.M.
        • O'Hoski P.
        • Singer J.
        • et al.
        A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing.
        Br J Haematol. 1992; 81: 579-584
        • Boral L.I.
        • Henry J.B.
        The type and screen: a safe alternative and supplement in selected surgical procedures.
        Transfusion. 1977; 17: 163-168
        • Havemann H.
        • Lichtiger B.
        Identification of previous erythrocyte alloimmunization and the type and screen at a large cancer center. A 4-year retrospective review.
        Cancer. 1992; 69: 552-555
        • Garratty G.
        How concerned should we be about missing antibodies to low incidence antigens?.
        Transfusion. 2003; 43: 844-847
        • Shulman I.A.
        The risk of an overt hemolytic transfusion reaction following the use of an immediate spin crossmatch.
        Arch Pathol Lab Med. 1990; 114: 412-414
        • Judd W.J.
        Requirements for the electronic crossmatch.
        Vox Sang. 1998; 74: 409-417
        • Schonewille H.
        • Van Zijl A.M.
        • Wijermans P.W.
        The importance of antibodies against low‐incidence RBC antigens in complete and abbreviated cross‐matching.
        Transfusion. 2003; 43: 939-944
        • Chapman J.F.
        • Milkins C.
        • Voak D.
        The computer crossmatch: a safe alternative to the serological crossmatch.
        Transfus Med. 2000; 10: 251-256
        • Cordle D.G.
        • Strauss R.G.
        • Snyder E.L.
        • Floss A.M.
        Safety and cost‐containment data that advocate abbreviated pretransfusion testing.
        Am J Clin Pathol. 1990; 94: 428-431
        • Safwenberg J.
        • Hogman C.F.
        • Cassemar B.
        Computerized delivery control – a useful and safe complement to the type and screen compatibility testing.
        Vox Sang. 1997; 72: 162-168
        • McClelland D.B.
        Treating a sick process.
        Transfusion. 2008; 38: 999-1003
        • Bolton-Maggs P.H.
        • Cohen H.
        Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety.
        Br J Haematol. 2013; 163: 303-314
      8. World Health Organization. A guide to establishing a National Haemovigilance System, 〈https://www.who.int/bloodsafety/haemovigilance/haemovigilance-guide/en/〉, 2006 [accessed 21 December 2021].

        • Hmida S.
        • Boukef K.
        Transfusion safety in the Maghreb region.
        Transfus Clin Biol. 2021; 28: 137-142
        • Folléa G.
        Rethinking blood components and patients: Patient blood management. Possible ways for development in France.
        Presse Med. 2016; 45: e273-e280
        • Gross I.
        • Shander A.
        • Sweeney J.
        Patient blood management and outcome, too early or not?.
        Best Pract Res Clin Anaesthesiol. 2013; 27: 161-172
        • Hare G.M.
        • Freedman J.
        • David
        • Mazer C.
        Review article: risks of anemia and related management strategies: can perioperative blood management improve patient safety?.
        Can J Anaesth. 2013; 60: 168-175
        • Theusinger O.M.
        • Felix C.
        • Spahn D.R.
        Strategies to reduce the use of blood products: a European perspective.
        Curr Opin Anaesthesiol. 2012; 25: 59-65
        • Carson J.L.
        • Guyatt G.
        • Heddle N.M.
        • et al.
        Clinical Practice Guidelines from the AABB: Red Blood Cell Transfusion Thresholds and Storage.
        JAMA. 2016; 316: 2025-2035
        • Peña J.R.
        • Saidman S.L.
        Anti-HLA antibody testing in hematology patients.
        Am J Hematol. 2015; 90: 361-364
        • Baldomero H.
        • Aljurf M.
        • Zaidi S.Z.A.
        • et al.
        East-Mediterranean (EMBMT) and African (AfBMT) Blood and Marrow Transplantation Groups and the Worldwide Network for Blood and Marrow Transplantation (WBMT). Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends.
        Bone Marrow Transplant. 2019; 54: 402-417
        • Bekadja M.A.
        • Brahimi M.
        • Osmani S.
        • et al.
        Hematopoietic stem cell transplantation in Algeria.
        Hematol Oncol Stem Cell Ther. 2017; 10: 311-314
        • Mohamed S.Y.
        • Fadhil I.
        • Hamladji R.M.
        • et al.
        Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group.
        Hematol Oncol Stem Cell Ther. 2011; 4: 81-93
        • Razgallah Khrouf M.
        • Achour L.
        • Thabti A.
        • et al.
        Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia.
        J Mark Access Health Policy. 2017; 5: 1335161
      9. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int 201;108:532-40.

        • Mahmoud H.K.
        • Fathy G.M.
        • Elhaddad A.
        • et al.
        Hematopoietic Stem Cell Transplantation in Egypt: Challenges and Opportunities.
        Mediterr J Hematol Infect Dis. 2020; 12e2020023
        • Bazarbachi A.
        • Zahreddine A.
        • Massoud R.
        • et al.
        Trends in hematopoietic stem cell transplant activity in Lebanon.
        Hematol Oncol Stem Cell Ther. 2017; 10: 315-320
        • Alavian S.M.
        • Aalaei-Andabili S.H.
        Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis.
        Hepat Mon. 2012; 12: 244-252
        • Tonbary Y.A.
        • Elashry R.
        • Zaki Mel S.
        Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, egypt: retrospective analysis.
        Mediterr J Hematol Infect Dis. 2010; 2e2010025
        • Cheraghali A.M.
        • Abolghasemi H.
        Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience.
        Haemophilia. 2009; 15: 487-493